Publication

Poster Presented at IgNS October 2019

PlasmaCap™ IG (Immunoglobulin) Poster
25 Oct, 2019 – Las Vegas, NV (October 25, 2019) – Evolve presented “Interim results of a novel 10% liquid intravenous immune globulin (IVIG) product’s Phase III Prospective, Open-Label Multicenter Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics in Adults and Children with Primary Immunodeficiency Disease (PIDD)”.

Publication

Poster Presented at AAAAI February 2019

PlasmaCap™ IG (Immunoglobulin) Poster
24 Feb, 2019 – San Francisco, CA (February 24, 2019) – Dr Richard Wasserman presented “Interim Safety Data in a Prospective, Open-Label, Multi-Center Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of PlasmaCap IG in Patients with Primary Immunodeficiency Diseases (PIDDs)”. Abstract published in Journal of Allergy Clinical Immunology (JACI).

Publication

Posters Presented at IgNS October 2018

PlasmaCap™ IG (Immunoglobulin) Clinical Trial Poster
PlasmaCap EBA™ Technology Poster
19 Oct, 2018 – Dallas, TX (October 19, 2018) – Evolve presented “A prospective, open-label, multicenter study of the efficacy, safety, tolerability, and pharmacokinetics of PlasmaCapTM IG (Immunoglobulin) in adults and children with primary immunodeficiency” and “PlasmaCap EBA™, an innovative method of isolating plasma proteins from human plasma”. Abstracts available here.